肾癌中Tiam 1的表达及临床意义

孟庆泽; 乔保平; 宫璀璀; 刘德海; 张喜卿

肾癌中Tiam 1的表达及临床意义

- 1 郑州大学第一附属医院泌尿外科(郑州, 450052);
- 2 中国人民解放军153 中心医院泌尿外科

详细信息

通讯作者: 乔保平,E-mail:zhangyaling@zzu.edu.cn

中图分类号: R737.2

收稿日期: 2011-11-16

Expression of Tiam 1 in renal carcinomas and its clinical significance

- 1. Department of Urology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, China;
- 2. Department of Urology, the 153 th Hospital of Chinese PLA

More Information

Corresponding author: QIAO Baoping, E-mail: zhangyaling@zzu.edu.cn

Received Date: 16 November 2011

摘要

摘要: 目的:探讨T淋巴瘤侵袭转移诱导因子1(Tiam 1)表达与肾癌发生、发展和转移的关系。方法:应用原位杂交及免疫组化方法检测正常肾组织、肾癌石蜡组织标本中Tiam 1 mRNA和蛋白的表达情况。用三种不同浓度2 μmol/L(T₁低浓度)、4 μmol/L(T₂中浓度)、8 μmol/L(T₃高浓度)的索坦干扰786-0细胞24 h、48 h、72 h;同时设正常对照组T₄(常规培养液)。应用TUNEL法检测各组作用48 h细胞凋亡率的变化。应用原位杂交及免疫组化方法检测各组Tiam 1 mRNA和蛋白的表达情况。结果:68例肾细胞癌组织中Tiam 1阳性表达率63.2%(43/68),有淋巴结转移组Tiam 1表达率明显高于无淋巴结转移组(P＜0.05),TNM分期为Ⅲ~Ⅳ期高于Ⅰ~Ⅱ期,差异有统计学意义(P＜0.01);对照组10例正常肾组织中Tiam 1表达均为阴性。Tiam 1基因在786-0细株中表达与肾癌组织中表达相一致。结论:Tiam 1表达与肾癌转移存在密切关系,Tiam 1 表达可作为肾癌转移过程中一个有价值的指标;索坦可抑制肾癌细胞的生长,诱导细胞的凋亡,可特异性抑制肾癌786-0细胞中Tiam 1蛋白及mRNA的表达,且具有浓度和时间依赖性。
- 肾癌 /
- T淋巴瘤侵袭转移诱导因子1 /
- 肿瘤转移 /
- 索坦 /
- 凋亡
Abstract: Objective:To investigate the influence of T lymphoma invasion and metastasis inducing factor 1(Tiam 1)expression on oncogenesis,progression and metastasis in renal carcinomas.Method:Immunohistochemistry and west-blot were used to detect Tiam 1 expression in normal renal epithelium,carcinomas,lymphatic metastasis of renal carcinoma and renal carcinoma cell lines 786-0.After the recovery and the incubation,the 786-0 cells were divided into different groups.:three different concentrations(2,4 and 8 μmol/L)of Sunitinib were used to treat 786-0 cells for 24,48 and 72 h.Result:The positive rate of Tiam 1 expression in renal carcinoma tissue was 63.2%(43/68),Furthermore,the Tiam 1 expression in renal carcinoma with lymph node metastasis was higher than that in renal carcinoma without lymph node metastasis(χ² = 5.620,P ＜0.05).which was correlated with clinical stsges (χ² = 15.308,P＜0.01).Normal renal tissue showed negative Tiam 1 stsining.Tiam 1 gene was also highly expressed in 786-0,The results were inconcordance with renal carcinoma tissue.Conclusion:Tiam 1 gene plays an important role in invasion and metastasis of renal carcinoma and is a metastasis-related gene.It may be an useful indicator of the tumor progression and metastasis in renal carcinoma.Sunitinib can specifically inhibit the expressions of Tiam 1 protein and mRNA in the renal cell carcinoma cell line 786-0.and was correlated with different concentrations and time,and can inhibit the cell growth,induce the cell apoptosis.
- renal neoplasms /
- T lymphoma invasion and metastasis inducing factor 1 /
- neoplasms metastasis /
- Sunitinib /
- apoptosis

HTML全文

参考文献(21)

[1]	HABETS G G,SCHOLTES E H,ZUYDGEEST D,et al.Identification of an invasion-inducing gene,Tiam-1,that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins[J].Cell,1994,77:537-549.
[2]	TERAMOTO H,CASTELLONC M D,MALCK R L,et al.Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transfornation by H-RasV12[J].Oncogene,2005,24:489-501.
[3]	BOUQUIER N,VIGNAL E,CHARRASSE S,et al.Acell active chemical GEF inhibitor selectively targetsthe Trio/RhoG/Rac1signaling pathway[J].Chem Bi-ol,2009,16:657-666.
[4]	MIYAMOTO M,IWASHITA S,YAMAGUCHI S,etal.Role of nm23in the regulation of cell shape and mi-gration via Rho family GTPase signals[J].Mol CellBiochem,2009,329:175-179.
[5]	MINOBE S,SAKAKIBARA A,OHDACHI T,et al.Rac is involved in the interkinetic nuclear migration ofcortical progenitor cells[J].Neurosci Res,2009,63:294-301.
[6]	G'ERARD A,van der KAMMEN R A,JANSSEN H,et al.The Rac activator Tiam 1controls efficient T-cell trafficking and route of transendothelial migration[J].Blood,2009,113:6138-6147.
[7]	KNEZEVIC I I,PREDESCU S A,NEAMU R F,et al.Tiam 1 and Rac1 are required for platelet-activating factor-induced endothelial junctional disassembly and increase in vascular permeability[J]..J Biol Chem,2009,284:5381-5394.
[8]	MALLIRI A,van der KAMMEN R A,CLARK K,etal.Mice deficient in the Rac activator Tiam 1are re-sistant to Ras-induced skin tumours[J].Nature,2002,417:867-871.
[9]	HABETS G G,van der KAMMEN R A,STAM J C,et al.Sequence of the human invasion-inducing TIAM1gene,its conservation in evolution and its expressionin tumor cell lines of different tissue origin[J].Onco-gene,1995,10:1371-1376.
[10]	WALCH A,SEIDL S,HERMANNST¨ADTER C,etal.Combined analysis of Rac1,IQGAP1,Tiam 1andE-cadherin expression in gastric cancer[J].ModPathol,2008,21:544-542.
[11]	MINARD M E,KIM L S,PRICE J E,et al.The roleof the guanine nucleotide exchange factor Tiam 1incellular migration,invasion,adhesion and tumor pro-gression[J].Breast Cancer Res Treat,2004,84:21-32.
[12]	LIU L,WANG S,ZHANG Q,et al.Identification ofpotential genes/proteins regulated by Tiam 1in color-ectal cancer by microarray analysis and proteome anal-ysis[J].Cell Biol Int,2008,32:1215-1222.
[13]	STEBEL A,BRACHETTI C,KUNKEL M,et al.Pro-gression of breast tumors is accompanied by a decreasein expression of the Rho guanine exchange factor Tiam1[J].Oncol Rep,2009,21:217-222.
[14]	QI Y,HUANG B,YU L,et al.Prognostic value of Ti-am 1and Rac1overexpression in nasopharyngeal car-cinoma[J].ORL J Otorhinolaryngol Relat Spec,2009,71:163-171.
[15]	DING Y,CHEN B,WANG S,et al.Overexpression of Tiam 1 in hepatocellular carcinomas predicts poor prognosis of HCC patients[J].Int J Cancer,2009,124:653-658.
[16]	LIU L,WU D H,DING Y Q.Tiam 1 gene expression and its significance in colorectal carcinoma[J].World J Gastroenterol,2005,11:705-707.
[17]	MOTZER R J,MICHAELSON M D,REDMAN B G,et al.Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2006,24:16-24.
[18]	MOTZER R J,HUTSON T E,TOMCZAK P,et al.Sunitinib vs.interferon in metastatic renal cell carcino-ma[J].N Engl J Med,2007,356:115-124.
[19]	DEMETRI G D,van OOSTEROM A T,GARRETT C R,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib:A randomized controlled trial[J].Lancet,2006,14:368:1329-1338.
[20]	GALLAGHER D J,MILOWSKY M I,GERST S R,etal.Final results of a phase II study of sunitinib in pa-tients(pts)with relapsed or refractory urothelial carci-noma(UC)[J].J Clin Oncol,2008,26(15suppl):5082.
[21]	SOCINSKI M A,NOVELLO S,SANCHEZ J M.Effi-cacy and safety of sunitinib in previously treated,ad-vanced non-small cell lung cancer(NSCLC):Prelimina-ry results of a multicenter phase II trial[J].J Clin On-col,2006,24/18S:7001.